Algorae Pharmaceuticals Limited
1AIASXLog in to unlock analysis summary free on one stock of your choice.
Log in to unlock detailed analysis free on one stock of your choice.
| AUD, millions | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | — | — | — |
| Gross Profit | — | — | — |
| Operating Income | -2 | -2 | -2 |
| Net Income | -2 | -2 | -2 |
Algorae Pharmaceuticals Limited, an AI-enabled pharmaceutical development company, engages in the research and development of living cells technologies primarily in Australia and New Zealand. The company's product pipeline includes AI-116, a novel combination drug candidate made up of donepezil and cannabidiol for the treatment of dementia, including Alzheimer's disease; AI-168, a novel combination drug candidate made up of a cannabinoid and an off-patent pharmaceutical ingredient for the treatment of cardiovascular disease, such as hypertension; and NTCELL, an alginate coated capsule product for the treatment of Parkinson's disease. It is also developing AlgaraeOS in partnership with the University of New South Wales, a drug discovery platform that uses artificial intelligence protocols and big data analytics for drug discovery and development; and AlgoraeRx, a commercial pharmaceutical division that source generic and specialty medicines from manufacturers. The company was formerly known as Living Cell Technologies Limited and changed its name to Algorae Pharmaceuticals Limited in September 2023. Algorae Pharmaceuticals Limited was founded in 1987 and is based in Melbourne, Australia.